Dbv Technologies SA to Discuss the EPOPEX Data Call Transcript

Nov 09, 2023 / 10:00PM GMT

Welcome to the DBV Technologies Interim Results from the open-label extension to EPITOPE Phase III trial Conference Call.

(Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Katie Matthews, Investor Relations. Please go ahead.

Katie Matthews -

Thank you. This afternoon, DBV Technologies issued a press release announced the interim results from our ongoing open-label extension to the EPITOPE Phase III trial, DBV's prior Phase III efficacy study, which evaluated Viaskin Peanut in toddlers ages 1 to 3 years old. This press release is available in the Press Releases section of the DPV Technologies website.

Before we begin, please note that today's call may include a number of forward-looking statements, including, but not limited to comments regarding the therapeutic potential of Viaskin Peanut and EPIT, our clinical and regulatory development plans, the timing and results of interactions with regulatory agencies, our forecast of our runway and the ability of any of our product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot